A Framework for Identifying Serum Exosomal Lipid Biomarkers in Alzheimer’s Disease

The escalating global burden of Alzheimer's disease (AD), projected to reach $16.9 trillion by 2050 with disproportionate impacts on low- and middle-income countries and racial minorities, underscores an urgent need for accessible early detection tools. Current therapies offer limited symptomatic relief but fail to halt neurodegeneration. Serum exosomal lipids, which reflect brain pathophysiology through blood-brain barrier crossing vesicles, present promising minimally invasive biomarkers. However, a standardized framework for their systematic development is lacking. We propose a structured three-phase approach comprising discovery, analytical validation, and clinical utility assessment. The discovery phase employs nontargeted lipidomics of serum exosomes from AD patients and controls integrated with machine learning to identify dysregulated pathways and prioritize candidate biomarkers. Analytical validation involves targeted quantification using UPLC-MS/MS to optimize sensitivity and specificity within complex matrices, with rigorous performance evaluation via receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) analysis in independent case-control cohorts establishing preliminary diagnostic cut-offs. Clinical utility assessment requires longitudinal evaluation in treated AD cohorts to correlate biomarker dynamics with disease progression or therapeutic response, refine diagnostic thresholds, and explore presymptomatic risk prediction. Implementing this framework demands multidisciplinary collaboration and strict ethical adherence. This strategy paves the way for clinically validated serum exosomal lipid biomarkers to enable presymptomatic detection and personalized risk stratification, ultimately mitigating AD's devastating socioeconomic impact.